Wybrane publikacje | Selected publications
2023
- J. Zhang, C. Koolmeister, J. Han, R. Filograna, L. Hanke, M. Àdori, D.J. Sheward, S. Teifel, S. Gopalakrishna, Q. Shao, Y. Liu, K. Zhu, R.A. Harris, G. McInerney, B. Murrell, M. Aoun, L. Bäckdahl, R. Holmdahl, M. Pekalski, A. Wedell, M. Engvall, G.B. Karlsson Hedestam, X. Castro Dopico, J. Rorbach 2023 „Antigen receptor stimulation induces purifying selection against pathogenic mitochondrial tRNA mutations” JCI Insight. 8(17):e167656.
2022
- A. Rubio García, A. Paterou, R.D. Powell Doherty, L.G. Landry, M. Lee, A.M. Anderson, H. Slawinski, R.C. Ferreira, D. Trzupek, A. Szypowska, L.S. Wicker, L. Teyton, N. Ternette, M. Nakayama, J.A. Todd, M.L. Pekalski 2022 „HLA-DQβ57, anti-insulin T cells and insulin mimicry in autoimmune diabetes” Medrxiv doi: https://doi.org/10.1101/2022.05.11.22274678
- N. Sandholm, A. Rubio García, M.L. Pekalski, J.R.J. Inshaw, A.J. Cutler, J.A. Todd 2022
„Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants” Sci Rep. 12(1):14137. - J.Y. Zhang, F. Hamey, D. Trzupek, M. Mickunas, M. Lee, L. Godfrey, J.H.M. Yang, M.L. Pekalski, J. Kennet, F. Waldron-Lynch, M.L. Evans, T.I.M. Tree, L.S. Wicker, J.A. Todd, R.C. Ferreira 2022 „Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes” Nat Commun. 13:7324.
2021
- A.G. Ziegler*, S. Arnolds, A. Kölln, P. Achenbach, R. Berner, E. Bonifacio, K. Casteels, H. Elding Larsson, M. Gündert, J. Hasford, O. Kordonouri, M. Lundgren, M. Oltarzewski, M.L. Pekalski*, M. Pfirrmann, M.D. Snape, A. Szypowska, J.A. Todd* 2021 „Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol” BMJ Open 11:e052449.
2019
- R.C. Ferreira, X. Castro Dopico, J.J. Oliveira, D.B. Rainbow, J.H. Yang, D. Trzupek, S.A. Todd, M. McNeill, M. Steri, V. Orrù, E. Fiorillo, D.J.M. Crouch, M.L. Pekalski, F. Cucca, T.I. Tree, T.J. Vyse, L.S. Wicker, J.A. Todd 2019 „Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression” Front Immunol. 10:2606.
2018
- E. Seelig, J. Howlett, L. Porter, L. Truman, J. Heywood, J. Kennet, E.L. Arbon, K. Anselmiova, N.M. Walker, and R. Atkar. (…) M. L. Pekalski (…) et al. 2018 The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. JCI insight 3(19):e99306.
2017
R.C. Ferreira, H.Z. Simons, W.S. Thompson, D.B. Rainbow, X. Yang, A.J. Cutler, J. Oliveira, X.C. Dopico, D.J. Smyth, N. Savinykh, J.A. Todd, L.S. Wicker, M.L. Pekalski 2017 „Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity” J Autoimmun. 84:75-86.
2016
- J.A. Todd, M. Evangelou*, A.J. Cutler*, M.L. Pekalski*, N.M. Walker, H.E. Stevens, L. Porter, D.J. Smyth, D.B. Rainbow, R.C. Ferreira et al. 2016 „Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial” PLoS Med. 13(10), e1002139.
2015
- R.C. Ferreira, H.Z. Simons, W.S. Thompson, A.J. Cutler, X.C. Dopico, D.J. Smyth, M. Mashar, H. H. Schuilenburg, N.M. Walker, D.B. Dunger, J.A. Todd, L.S. Wicker, and M. L. Pekalski. 2015 IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 58:781-790.
- X.C. Dopico, M. Evangelou, R.C. Ferreira, H. Guo, M.L. Pekalski, D.J. Smyth, N. Cooper, O.S. Burren, A.J. Fulford, and B.J. Hennig. 2015. Widespread seasonal gene expression reveals annual differences in human immunity and physiology. Nature Commun. 6, 7000
- L.A Truman,., M.L. Pekalski, P. Kareclas, M. Evangelou, N.M. Walker, J. Howlett, A.P. Mander, J. Kennet, L.S. Wicker, and S. Bond. 2015 Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. BMJ Open 5(12):e009799.
2014
- R.C. Ferreira, H. Guo, R.M.R. Coulson, D.J. Smyth, M.L. Pekalski, O.S. Burren, A.J. Cutler, J.D. Doecke, S. Flint, and E.F. McKinney. 2014. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes 63:2538-2550.
2013
- M.L. Pekalski, R.C. Ferreira, R.M.R. Coulson, A.J. Cutler, H. Guo, D.J. Smyth, K. Downes, C.A. Dendrou, X.C. Dopico, L. Esposito 2013 „Postthymic expansion in human CD4 naive T cells defined by expression of functional high-affinity IL-2 receptors” J Immunol. 190(6), 2554–2566.